Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Désirée Mfm van der HeijdeMaxime DougadosYing-Chou ChenMaria GreenwaldEdit DrescherRena KlarLi XieInmaculada de la TorreTerence P RooneySarah L WittDouglas E SchlichtingStephanie de BonoPaul EmeryPublished in: RMD open (2018)
Once daily oral baricitinib inhibited radiographic progression of structural joint damage in patients with an inadequate response or intolerance to csDMARDs over 48 weeks. The most robust benefit was seen for the 4 mg dose.